Supervisory Bioinformatics Scientist
Children's Hospital of Philadelphia
Jo Lynne’s broad research interests lie in identifying and validating novel coding, noncoding, epigenetic, and/or transcriptional mechanisms contributing to oncogenesis, tumor evolution, and progression/relapse of pediatric high-grade diffuse astrocytic tumors. She combines molecular, genomics, and machine learning approaches to discover and validate novel actionable oncogenic targets and/or pathways with the overall goal of informing current therapeutic regimens leading to future clinical trials.
Children’s Hospital of Philadelphia
Molecular Mechanisms and Functional Impact of Aberrant Splicing in Diffuse Midline Gliomas
A comprehensive approach is needed to advance the understanding and clinical care options for patients with diffuse midline gliomas (DMGs). Using DMG samples provided by the Children’s Brain Tumor Network, researchers seek to identify avenues for new therapies.
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test
Diffuse Intrinsic Pontine Glioma
A presumptive diagnosis of DIPG based on classic imaging features, in the absence of a histologic diagnosis, has been routinely employed. Increasingly however, histologic confirmation is obtained for both entry into research studies and molecular characterization of the tumor. New approaches with